Date: 01-Sep-2020

TS Govt Launches Make In Telangana Campaign To Double Investments In Pharma Healthcare & Life Sciences Sectors To $100 Bn By 2030

The state government of Telangana has started pitching for ‘Make in Telangana’ initiative and has set out its vision of doubling investments to pharma, healthcare and life sciences sectors to $100 billion by 2030, by attracting investors from across the globe.

Advocating state government’s vision, Shakthi Nagappan, director of life sciences, government of Telangana, said that in the next 10 years, the state of Telangana is going to become the global hub for innovation and research. Accordingly the government has taken pro-active measures and taken historical decisions to set up Asia’s largest Pharma City project, in addition to establishing Genome Valley 2.0, Medical Devices Park, Digital Medicines Hub, B-Hub, among others.

“Telangana has the apt platform to invest in pharma, healthcare and life-sciences sectors. Not just established the right infrastructure but has also come out with a new Industrial Policy to ensure ease of doing business in the state for the investors,” said the life sciences director.

While speaking at a panel discussion organized by the Confederation of Indian Industry (CII) on the topic of ‘Make in Telangana’, Nagappan highlighted that Telangana is having infinite opportunities and world class infrastructure particularly for pharma, life sciences, healthcare sectors and shed light on the strengths, policies and the right ecosystem for the investors particularly in the life-sciences segment.

Lead experts from Indian Immunologicals Limited Dr. Anand Kumar; Madan R Krishnan, vice president MITG APAC & VP-MD India Subcontinent (South Asia), Medtronic; Krishna Kanumuri, managing director, Sai Life Sciences; and Sanjay Singh, Partner, Deal Advisory Head, Life Sciences Sector took part in the panel discussion.

Talking about how Hyderabad has emerged as the vaccine capital of the world in the presence of good institutes such as CCMB, Dr. K Anand Kumar stated that the city was driving growth of the pharma industry which came in very handy for early manufacturing in vaccine.

Krishna Kanumuri stated that the ecosystem of Hyderabad facilitated the growth of Sai Life Sciences. Institutes such as Indian Institute of Chemical Technology (IICT) in Hyderabad have been instrumental in starting a lot of companies in Hyderabad. Speaking on the overall policy landscape for the life sciences sector in India and Telangana, he mentioned that while the policy environment in India is absolutely up to the required standard, the government needs to work on the publicity of the policy. He also pointed out that the focus areas should be innovation, training, and the next generation research.

Another expert Madan Krishnan noted that the talent pool, consistent policies and supporting business environment in Hyderabad have been primary reasons for Medtronic’s choice to make one of their largest investments here. He also pointed out that the center in Hyderabad has over 150 patents and more than 400 IP disclosures to its name. He stated that with “Make in India”, the idea of design, research and development in India should also be considered as the real transformative engines. He pointed out that continuity and predictability policy in India can go a long way in inviting foreign investors.

“Companies across the globe are extensively looking at India for their expansion plans mainly because of conducive factors such as proximity to R&D, stability of policy and reasonable tax regime, partnership potential with the government etc.”

He also pointed out that making available the required plug and play infrastructure for companies to start their operations quickly will attract more investments and Telangana taking up gigantic projects like the Hyderabad Pharma City and Medical Devices Park, the state is definitely moving in the right direction to realize its goal of ‘Make in Telangana’.